• A new immunotherapy drug that delays the development of type 1 diabetes was given the green light by U.S. regulators.
• Teplizumab focuses on addressing the root cause of the condition, rather than the symptoms, which experts say ushers in a “new era” in treatment.
• The drug works by reprogramming the body’s immune system and preventing it from mistakenly attacking pancreatic cells, which produce insulin.

Tagged: Health & Wellness